Please login to the form below

Not currently logged in
Email:
Password:

Abilify Maintena

This page shows the latest Abilify Maintena news and features for those working in and with pharma, biotech and healthcare.

Lundbeck’s key products shine in Q2 but problems remain

Lundbeck’s key products shine in Q2 but problems remain

Sales of Rexulti (brexpiprazole), Abilify Maintena (aripiprazole), Trintellix (vortioxetine) and Northera (droxidopa) increased by 20% to 44% in the quarter, resulting in overall sales of those key products coming in above

Latest news

  • Indivior push to diversify boosted by schizophrenia drug approval Indivior push to diversify boosted by schizophrenia drug approval

    Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna. ... It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    off the patent cliff in recent years and seen steep sales decline as a result, although a long-acting depot formulation (Abilify Maintena) is still making gains. ... Abilify. Lundbeck and Otsuka are also evaluating the drug in a phase II trial involving

  • Otsuka refiles 'digital' medicine for mental illness Otsuka refiles 'digital' medicine for mental illness

    The so-called 'digital medicine' consists of Otsuka's Abilify (aripiprazole) embedded with Proteus' ingestible sensor that is the size of a grain of sand, which records medication ingestion. ... The company's long-acting formulation Abilify Maintena is

  • Surging sales of Lundbeck's CNS drugs assist recovery Surging sales of Lundbeck's CNS drugs assist recovery

    Schizophrenia depot Abilify Maintena (aripiprazole) was up 78% to DKK 279m, and new drug for high blood pressure associated with Parkinson's disease - Northera (droxidopa) - romped away with a 136% rise ... Schultz said he was pleased with the sales

  • Allergan and Gedeon finally get antipsychotic green light Allergan and Gedeon finally get antipsychotic green light

    Once-monthly examples include Otsuka/Lundbeck's Abilify Maintena (aripiprazole) and Johnson and Johnson's Invega Sustenna (paliperidone palmitate), while J&J is also developing a three-monthly paliperidone depot that

More from news
Approximately 2 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    At the end of February, the FDA approved Abilify Maintena (aripiprazole), an intramuscular extended-release depot formulation for the treatment of schizophrenia and the first commercialised product to evolve from this ... injectable in 14 European

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...

Infographics